Home > Rheumatology > EULAR 2018 > Psoriasis and Psoriatic Arthritis > Apremilast Significantly Improves Psoriatic Arthritis in the Long-term

Apremilast Significantly Improves Psoriatic Arthritis in the Long-term

Conference
EULAR 2018
Trial
Phase 3, PALACE

Apremilast has demonstrated sustained and clinically meaningful improvements in signs and symptoms of PsA, as well as in physical function in patients who continued treatment over 5 years. Apremilast also demonstrated a favourable safety profile and was generally well tolerated at 5 years.

Apremilast is an oral phosphodiesterase 4 inhibitor that inhibits the PDE4 intracellular pathway of inflammatory mediators associated with the pathogenesis of PsA.[1] Long-term efficacy and safety of treatment with apremilast were evaluated for up to 5 years in patients with active PsA by using data from the phase 3 PALACE 1, 2, and 3 studies. Eligible patients had active PsA (duration >6 months, meeting CASPAR criteria, ≥3 SJC, and ≥3 TJC) despite prior conventional treatment with DMARDs and/or biologics.

A total of 1,493 patients were randomised at baseline (1:1:1) to receive placebo, 30 mg apremilast BID, or 20 mg apremilast BID. Placebo subjects were re-randomised 1:1 to 30...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on